Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announces that it has begun work with the UK government’s CONDOR programme to evaluate and clinically validate the high
Testing Therapies, Antivirals and Vaccines Avacta Group entered into a collaboration with Integumen plc to evaluate recently generated Affimer reagents that bind the SARS-COV-2 spike protein for the detection of the coronavirus in
Life sciences business Avacta Group has become the second Yorkshire firm to partner with Integumen on Covid-19 detection systems for wastewater. The Wetherby-based listed firm has entered into a collaboration
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that it has entered into a collaboration with Integumen plc (LON:SKIN) to evaluate recently generated Affimer reagents that
In this interview, Alastair Smith discusses our development of a rapid antigen test for SARS-Cov-2 and the progress of our preCISIONTM and Affimer® based cancer therapies. Watch below. Avacta Group Plc (LON:AVCT) offers reagents
Avacta Group has won Technology Company of the Year at the Small Cap 2020 Awards. Over 200 attendees, all supporters of the small cap community congregated online at the (optional)
Avacta Group’s Alistair Smith discusses progress of the COVID-19 antigen test strips, the next steps in development with Cytiva and how some of the Affimer reagents can prevent the virus from getting into human cells in this exclusive interview with DirectorsTalk.
When a disease outbreak occurs, the first stage of the response is detection. In both the Zika and COVID-19 outbreaks, WHO identified effective diagnostics as vital tools in disease management in order
In this video, Avacta’s Chief Executive Officer Alastair Smith explains how diagnostic test performance is measured. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer technology for diagnostic
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss its latest positive update on its rapid antigen test and affimer blocking reagent. Alastair provides more details around the antigen
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
